Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The high-grade endometrial sarcoma: a rare entity.

S M Lenhard1, M Untch, I Himsl

  • 1Department of Obstetrics and Gynecology, Ludwig-Maximilians-University Munich, Campus Grosshadern, Marchioninistrasse 15, 80337, Munich, Germany. miriam.lenhard@med.uni-muenchen.de

Archives of Gynecology and Obstetrics
|November 29, 2005
PubMed
Summary

Endometrial stromal sarcoma (ESS) is a rare uterine cancer. Standard surgical treatment involves hysterectomy and adnexectomy, but optimal adjuvant therapies require further research for this challenging diagnosis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Concordance between clinician-reported toxicities and patient-reported symptom severity in early-stage breast cancer: an analysis of the randomized phase III PANTHER trial.

ESMO open·2026
Same author

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.

ESMO open·2025
Same author

Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX).

ESMO open·2025
Same author

Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)].

ESMO open·2024

Area of Science:

  • Gynecologic Oncology
  • Rare Cancers
  • Surgical Pathology

Background:

  • Endometrial stromal sarcoma (ESS) is a rare uterine malignancy with low incidence.
  • ESS is subclassified into high-grade and low-grade types, with differing prognoses.
  • Limited evidence-based data exists for standardized ESS therapy.

Observation:

  • A 32-year-old obese nulligravida presented with persistent vaginal bleeding.
  • Gynecological ultrasound revealed a large, vascularized uterine mass.
  • Histological examination confirmed a 7 cm non-differentiated endometrial sarcoma with ovarian infiltration.

Findings:

  • The patient underwent hysterectomy, adnexectomy, and pelvic lymphonodectomy.
  • The final pathology reported a non-differentiated endometrial sarcoma.

Related Experiment Videos

  • Twenty-five tumor-free lymph nodes were identified.

    • Implications:

    • Standard surgical management for resectable ESS includes hysterectomy and bilateral adnexectomy.
    • Adjuvant radio- or chemotherapy data in ESS is scarce, necessitating further investigation.
    • ESS management is a multidisciplinary challenge requiring individualized treatment strategies based on international protocols.